Liquidia Technologies, Inc. will be submitting a new drug application to the Food and Drug Administration for LIQ861 early in the first quarter of 2020, according to a Securities and Exchange Commission filing on Wednesday.

The filing indicates that the company completed clinical tests for its Phase 3 development program in its investigational treatment plan for pulmonary arterial hypertension.

A meeting with the FDA regarding the chemistry, manufacturing and controls aspects of the plan has already been conducted. Another meeting concerning the clinical and nonclinical contents of the NDA is expected to be held in November.

Liquidia Technologies is a bio-pharmaceutical company headquartered in Morrisville. Shares of Liquidia were trading at $3.62 on Friday, up three cents.